Tue, June 21, 2022

Gregory Renza Maintained (ACAD) at Buy with Decreased Target to $26 on, Jun 21st, 2022

Gregory Renza of RBC Capital, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Buy with Decreased Target from $32 to $26 on, Jun 21st, 2022.

Gregory has made no other calls on ACAD in the last 4 months.



There are 5 other peers that have a rating on ACAD. Out of the 5 peers that are also analyzing ACAD, 3 agree with Gregory's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Vamil Divan of "Mizuho" Maintained at Hold with Decreased Target to $27 on, Tuesday, April 19th, 2022
  • Salveen Richter of "Goldman Sachs" Maintained at Hold with Decreased Target to $24 on, Monday, March 7th, 2022
  • Tazeen Ahmad of "B of A Securities" Maintained at Hold with Decreased Target to $31 on, Tuesday, March 1st, 2022


These are the ratings of the 2 analyists that currently disagree with Gregory


  • Sumant Kulkarni of "Canaccord Genuity" Upgraded from Hold to Strong Buy and Increased Target to $31 on, Wednesday, March 16th, 2022
  • Jason Butler of "JMP Securities" Maintained at Buy with Decreased Target to $35 on, Tuesday, March 1st, 2022